Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid

Journal of Pathology

Volumn 186, Issue 3, 1998, Pages 287-291

  Zanetti, Antonio ^a   Stoppacciaro, Antonella ^a   Marzullo, Antonella ^a   Ciabatta, Maria ^a   Fazioli, Francesca ^b   Prat, Maria ^c   Comoglio, Paolo M ^c   Baroni, Carlo D ^a   Ruco, Luigi P ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b S Raffaele Sci Institute HSR Dibit   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Dipto di Medicina Sperimentale   (Italy)

Author keywords

MET oncogene; Met protein; Papillary carcinoma; Thyroid; Thyroid tumours; uPAR; Urokinase type plasminogen activator receptor

Indexed keywords

GROWTH FACTOR RECEPTOR; MESSENGER RNA; SCATTER FACTOR; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GOITER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SCLEROSIS; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDITIS;

EID: 0031761620     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199811)186:3<287::AID-PATH175>3.0.CO;2-X     Document Type: Article

References (33)

1. Carcangiu ML. Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985; 55: 805-828.
2. Rosai J, Carcangiu ML, De Lellis LA. Atlas of Tumor Pathology, Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology, 1992..
3. Prat M, Narsimhan R, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM. The receptor encoded by the human c-WET oncogene is expressed in hepatocytes, epithelial cells and solid tumours. Int J Cancer 1991; 49: 323-328.
4. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6: 1997-2003.
5. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-met-hgf receptor gene in human thyroid carcinomas. Oncogene 1992; 7: 2549-2553.
6. Ruco LP, Ranalli T, Marzullo A, et al. Expression of Met protein in thyroid tumors. J Pathol 1996; 180: 266-270.
7. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989; 339: 155-156.
8. Gonzalti-Haces M, Seth A, Park M, Copeland T, Oroszlan S, Vande Woude GF. Characterization of the tpr-met oncogene p65 and the met protooncogene p140 protein-tyrosine kinases. Biochemistry 1988; 85: 21-25.
9. Giordano S, Di Renzo MF, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM. Biosynthesis of the protein encoded by the c-MET proto-oncogene. Oncogene 1989; 4: 1383-1388.
10. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
11. Naldini L, Vigna E, Narimhan R, et al. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-met. Oncogene 1991; 6: 501-504.
12. Gherardi E, Soker M. Hepatocytes and scatter factor. Sature 1990; 346: 228.
13. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991; 10: 2867-2878.
14. Naldini L, Tamagnone L, Vigna E, et cl. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992; 11: 4825-4833.
15. Nusrat A, Parkos CA, Bacarra AE, et al. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and non-transformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. J Clin Invest 1994; 93: 2056-2065.
16. Rosen EM, Nigam SK, Goldberg I. Scatter factor and c-Met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994; 127: 1783-1787.
17. Blasi F, Vassalli JD, Dano K. Urokinase type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801-804.
18. Nielsen LS, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988; 263: 2358-2363.
19. Pike C, Kristensen P, Ralfkiaer E, et al. Urokmase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-1067.
20. Quax PHA, Van Muijen GNP, Weening-Verhoeff EJD, et al. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991; 115: 191-199.
21. Reith A, Rucklidge GJ. Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem Biophys Res Commun 1992; 186: 348-354.
22. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992; 50: 871-873.
23. Ploug M. Ronne E, Behrendt N, Jansen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxy-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266: 1926-1933.
24. Estreicher A, Muhlhauser J, Carpentier J-L, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111: 783-792.
25. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. Upresulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993; 122: 673-684.
26. Prat M, Crepaldi T, Gandino L, Giordano S, Longati P, Comoglio PM. C-terminal truncated forms of Met. the hepatocyte growth factor receptor. Mol Cell Biol 1991; 11: 5954-5962.
27. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage or the urokinase receptor substitutes for the agonistinduced chemotactic effect. EMBO J 1996; 15: 1572-1582.
28. Stoppacciaro A, Melani C, Parenza M, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation of T cell-produced interferon g. J Exp Med 1993; 178: 151-161.
29. Monsky WL, Chen W-T. Proteases of cell adhesion proteins in cancer. Semin Cancer Biol 1993; 4: 251-258.
30. Basbaum CB, Werb Z. Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 1996; 98: 731-738.
31. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-signalling in human cells concomitant with induction of the urokinase proteohsis network . Mol Cell Biol 1996; 16: 1115-1125.
32. Katoh R, Bray CE, Suzuki K, et al. Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum Pathol 1995; 26: 139-146.
33. Shimizu T, Usuda N, Yamanda T, Sugenoya A, Futoshi I. Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies. Cancer 1993; 71: 2807-2812.